Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03261947
Title A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

colon adenocarcinoma

pancreatic adenocarcinoma

rectum adenocarcinoma

lung squamous cell carcinoma

esophagus squamous cell carcinoma

Therapies

Simurosertib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Sarah Cannon Research Institute Oncology Research Consortium Denver Colorado 80218 United States Details
Sarah Cannon Research Institute Sarasota Florida 34232 United States Details
Allina Health Virginia Piper Cancer Institute Minneapolis Minnesota 55404 United States Details
Siteman Cancer Center Saint Louis Missouri 63110 United States Details
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89119 United States Details
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
SCRI - Tennessee Oncology - Nashville - Southern Hills Clinic Nashville Tennessee 37203 United States Details
Virginia Mason Medical Center Seattle Washington 98101-2756 United States Details
National Cancer Center Hospital East Kashiwa Chiba 277-8577 Japan Details
National Cancer Center Hospital Chuo-ku Tokyo 104-0045 Japan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field